Comparison study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus - DURATION-NEO-2

Study identifier:BCB120

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

Medical condition

Diabetes Type 2

Phase

Phase 3

Healthy volunteers

No

Study drug

Exenatide once weekly suspension, Exenatide once weekly suspension, Exenatide once weekly suspension, Sitagliptin, Sitagliptin, Sitagliptin, Placebo

Sex

All

Enrollment

365

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2013
Primary Completion Date: 01 Apr 2014
Study Completion Date: 01 Apr 2014

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria